Epic Wound Care has confirmed that an initial order of its ActJel gauze used to address advanced bleeding control, was shipped to Tel Aviv, Israel, for sale in pharmacies and retail outlets. The product is marketed under ActCel, ActJel, HemoStyp and ABC Gauze, all of which are marks of the company and its distributor.

Epic Wound Care produces a hemostatic gauze, a collagen-like natural substance created from chemically treated cellulose. It is designed to address severe bleeding in wound care applications. Upon contact with moisture, the gauze forms a gel-like substance that acts as a hemostatic agent to address bleeding quickly. Once bleeding has ceased and coagulation has occurred, the product can be rinsed away with saline solution or water.

Craig Bluth, CEO of Coreva Health Science, said: “This is a event for the company and its distribution network. We believe that this order signifies increasing acceptance of Epic Wound Care’s gauze product and the foundation of a growing market for the product. We are optimistic that this is beginning of a series of orders that will follow.”